Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | PGR | P06401 | 2/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29875309 | 0.94 | PFKFB3 (0.71) | PFKFB3MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL2831061 | 0.94 | PFKFB3 (0.71) | PFKFB3MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL29369447 | 0.94 | PFKFB3 (0.71) | PFKFB3MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL7365696 | 0.90 | KDM4E (0.64) | PFKFB3MEN1KMT2ATSHRPGR | |
| SCHEMBL7366821 | 0.87 | AKR1C3 (0.67) | PFKFB3MEN1KMT2ATSHRPGR | |
| SCHEMBL664321 | 0.87 | KMT2A (0.75) | MEN1KMT2ATSHRALDH1A1PGR | |
| SCHEMBL30702318 | 0.86 | PFKFB3 (0.76) | PFKFB3MEN1KMT2ATSHRAKR1C3 | |
| SCHEMBL4063367 | 0.86 | PFKFB3 (0.76) | PFKFB3MEN1KMT2ATSHRAKR1C3 | |
| SCHEMBL30702319 | 0.86 | PFKFB3 (0.76) | PFKFB3MEN1KMT2ATSHRAKR1C3 | |
| SCHEMBL8241750 | 0.85 | TCF4 (0.64) | PFKFB3MEN1KMT2ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504431-B2 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504431-B2 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL- MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL- MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | CACNA1F, CACNA1A, CACNA1D | PFKFB3 2451/4885MEN1 2007/4885KMT2A 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.